Cognition Therapeutics Inc (CGTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cognition Therapeutics Inc (CGTX) has a cash flow conversion efficiency ratio of -0.155x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.65 Million) by net assets ($36.53 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cognition Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Cognition Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read CGTX liabilities breakdown for a breakdown of total debt and financial obligations.
Cognition Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cognition Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Deoleo S.A
MC:OLE
|
-0.007x |
|
Kapston Services Limited
NSE:KAPSTON
|
0.016x |
|
Creepy Jar SA
WAR:CRJ
|
0.029x |
|
Singha Estate Public Company Limited
BK:S-R
|
0.034x |
|
Fossil Group Inc
NASDAQ:FOSL
|
-0.231x |
|
Codexis Inc
NASDAQ:CDXS
|
-0.200x |
|
Oriental Aromatics Limited
NSE:OAL
|
-0.046x |
|
Masisa
SN:MASISA
|
0.057x |
Annual Cash Flow Conversion Efficiency for Cognition Therapeutics Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Cognition Therapeutics Inc from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Cognition Therapeutics Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $18.75 Million | $-28.47 Million | -1.519x | -132.03% |
| 2023-12-31 | $24.47 Million | $-16.02 Million | -0.654x | -42.14% |
| 2022-12-31 | $40.25 Million | $-18.53 Million | -0.460x | -550.21% |
| 2021-12-31 | $51.27 Million | $-3.63 Million | -0.071x | -240.65% |
| 2020-12-31 | $-68.18 Million | $-3.43 Million | 0.050x | -5.05% |
| 2019-12-31 | $-58.42 Million | $-3.10 Million | 0.053x | -- |
About Cognition Therapeutics Inc
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2… Read more